| Year |
Citation |
Score |
| 2020 |
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet. Oncology. PMID 32919526 DOI: 10.1016/S1470-2045(20)30445-9 |
0.309 |
|
| 2020 |
Prabhu SA, Moussa O, Miller WH, Del Rincón SV. The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma. International Journal of Molecular Sciences. 21. PMID 32517051 DOI: 10.3390/Ijms21114055 |
0.362 |
|
| 2020 |
Yang W, Khoury E, Guo Q, Prabhu SA, Emond A, Huang F, Gonçalves C, Zhan Y, Plourde D, Nichol JN, Dahabieh MS, Miller WH, Del Rincón SV. MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression. Oncogene. PMID 32132651 DOI: 10.1038/S41388-020-1240-5 |
0.328 |
|
| 2020 |
Chu QS, Jonker DJ, Provencher DM, Miller WH, Bouganim N, Shields AF, Shapiro G, Sawyer MB, Lheureux S, Samouelian V, Gotlieb WH, Esfahani K, Zaknoen SL, Smith PS, Owen J, et al. A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology. 38: 3581-3581. DOI: 10.1200/Jco.2020.38.15_Suppl.3581 |
0.359 |
|
| 2020 |
Miller WH, Chu QS, Bouganim N, Jonker DJ, Batist G, Buhlaiga NJ, Lheureux S, Spratlin JL, Alcindor T, Smith PS, Owen J, Zaknoen SL, Stille JR, Fortier C, Vincett D, et al. A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer. Journal of Clinical Oncology. 38: 3579-3579. DOI: 10.1200/Jco.2020.38.15_Suppl.3579 |
0.346 |
|
| 2020 |
Dummer R, Sandhu SK, Miller WH, Butler MO, Blank CU, Muñoz-Couselo E, Burris HA, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich A, Mauch C, Kleha J, et al. A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2). Journal of Clinical Oncology. 38: 10022-10022. DOI: 10.1200/Jco.2020.38.15_Suppl.10022 |
0.325 |
|
| 2020 |
Maio M, Carlino M, Joshua A, McWhirter E, Ribas A, Ascierto P, Miller W, Butler M, Ferrucci P, Zielinski R, Vecchio MD, Gasal E, Ghori R, Diede S, Croydon E, et al. P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma Journal For Immunotherapy of Cancer. 8. DOI: 10.1136/Lba2019.16 |
0.345 |
|
| 2019 |
Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, et al. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31870883 DOI: 10.1016/J.Jtho.2019.12.109 |
0.365 |
|
| 2019 |
Abdul Razak AR, Miller WH, Uy GL, Blotner S, Young AM, Higgins B, Chen LC, Gore L. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. Investigational New Drugs. PMID 31734832 DOI: 10.1007/S10637-019-00869-2 |
0.338 |
|
| 2019 |
Esfahani K, Al-Aubodah TA, Thebault P, Lapointe R, Hudson M, Johnson NA, Baran D, Bhulaiga N, Takano T, Cailhier JF, Piccirillo CA, Miller WH. Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nature Communications. 10: 4712. PMID 31624262 DOI: 10.1038/S41467-019-12628-1 |
0.318 |
|
| 2019 |
Kumar R, Van de Vijver M, Tortora G, Ciardiello F, Goldkorn T, Miller WH, Norton L. A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. Cancer Research. PMID 31213466 DOI: 10.1158/0008-5472.Can-19-0989 |
0.331 |
|
| 2019 |
Guo Q, Huang F, Goncalves C, Del Rincón SV, Miller WH. Translation of cancer immunotherapy from the bench to the bedside. Advances in Cancer Research. 143: 1-62. PMID 31202357 DOI: 10.1016/Bs.Acr.2019.03.001 |
0.342 |
|
| 2019 |
Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nature Medicine. PMID 31171879 DOI: 10.1038/S41591-019-0476-5 |
0.362 |
|
| 2019 |
Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nature Medicine. PMID 31011205 DOI: 10.1038/S41591-019-0424-4 |
0.34 |
|
| 2019 |
Hellmann MD, Kim TW, Lee CB, Goh BC, Miller WH, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, et al. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30918950 DOI: 10.1093/Annonc/Mdz113 |
0.357 |
|
| 2019 |
Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, Belanger K, Miller W, Jamal R, Letarte N, Wong P, Routy B. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology. 8: e1568812. PMID 30906663 DOI: 10.1080/2162402X.2019.1568812 |
0.344 |
|
| 2019 |
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH, Gurney H, Schmidinger M, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine. PMID 30779531 DOI: 10.1056/Nejmoa1816047 |
0.3 |
|
| 2019 |
Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, ... ... Miller WH, et al. MNK1/NODAL signaling promotes invasive progression of breast ductal carcinoma in situ. Cancer Research. PMID 30659022 DOI: 10.1158/0008-5472.Can-18-1602 |
0.33 |
|
| 2019 |
Esfahani K, Meti N, Miller WH, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 191: E40-E46. PMID 30642824 DOI: 10.1503/Cmaj.180870 |
0.323 |
|
| 2019 |
Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH, Delord J, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, et al. Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct073 |
0.383 |
|
| 2018 |
Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, ... ... Miller W, et al. An open-label, multicentre safety study of vemurafenib in patients with BRAF-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. European Journal of Cancer (Oxford, England : 1990). 107: 175-185. PMID 30580112 DOI: 10.1016/J.Ejca.2018.11.018 |
0.34 |
|
| 2018 |
Robichaud N, Hsu BE, Istomine R, Alvarez F, Blagih J, Ma EH, Morales SV, Dai DL, Li G, Souleimanova M, Guo Q, Del Rincon SV, Miller WH, Ramón Y Cajal S, Park M, et al. Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils. Proceedings of the National Academy of Sciences of the United States of America. PMID 29463754 DOI: 10.1073/Pnas.1717439115 |
0.363 |
|
| 2018 |
Nemunaitis J, Young A, Ejadi S, Miller W, Chen LC, Nichols G, Blotner S, Vazvaei F, Zhi J, Razak A. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. PMID 29368050 DOI: 10.1007/S00280-018-3521-Z |
0.346 |
|
| 2018 |
Miller WH, Jamal R, Cocolakis E, Thebault P, Friedmann JE, Kazemi S, Dionne J, Cailhier J, Lepage S, Belanger K, Ayoub JM, Le H, Lambert C, Hajjar JE, Kempen LV, et al. Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP). Journal of Clinical Oncology. 36: 185-185. DOI: 10.1200/Jco.2018.36.5_Suppl.185 |
0.314 |
|
| 2018 |
Moldoveanu D, Lajoie M, Huang X, Lvova M, Tse JY, Lyle S, Protopopov A, Russel M, Dankner M, Del Rincon S, Van Kempen L, Spatz A, Miller WH, Petrecca K, Wang B, et al. Multi-platform characterization of cutaneous melanoma from patients treated with immune checkpoint inhibitors. Journal of Clinical Oncology. 36: e15071-e15071. DOI: 10.1200/Jco.2018.36.15_Suppl.E15071 |
0.325 |
|
| 2018 |
Chung HC, Lopez-Martin JA, Kao SC, Miller WH, Ros W, Gao B, Marabelle A, Gottfried M, Zer A, Delord J, Penel N, Jalal SI, Xu L, Zeigenfuss S, Pruitt SK, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. Journal of Clinical Oncology. 36: 8506-8506. DOI: 10.1200/Jco.2018.36.15_Suppl.8506 |
0.315 |
|
| 2018 |
Dummer R, Schadendorf D, Nathan P, Tawbi H, Robert C, Ascierto PA, Ribas A, Lebbé C, Mandala M, Yamazaki N, Richtig E, Miller WH, Gasal E, Kaper M, Brase JC, et al. Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct182 |
0.327 |
|
| 2017 |
Jamal R, Lapointe R, Cocolakis E, Thébault P, Kazemi S, Friedmann JE, Dionne J, Cailhier JF, Bélanger K, Ayoub JP, Le H, Lambert C, El-Hajjar J, van Kempen LC, Spatz A, ... Miller WH, et al. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. Journal For Immunotherapy of Cancer. 5: 83. PMID 29157311 DOI: 10.1186/S40425-017-0290-X |
0.329 |
|
| 2017 |
Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, ... ... Miller WH, et al. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. The Journal of Clinical Investigation. PMID 29035277 DOI: 10.1172/Jci91258 |
0.373 |
|
| 2017 |
Dahabieh MS, Ha Z, Di Pietro E, Nichol JN, Bolt AM, Goncalves C, Dupéré-Richer D, Pettersson F, Mann KK, Braverman NE, Del Rincón SV, Miller WH. Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis. Cell Death and Differentiation. PMID 28731463 DOI: 10.1038/Cdd.2017.115 |
0.348 |
|
| 2017 |
Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016718023. PMID 28671856 DOI: 10.1200/Jco.2016.71.8023 |
0.363 |
|
| 2017 |
Esfahani K, Miller WH. Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. The New England Journal of Medicine. 376: 1989-1991. PMID 28514612 DOI: 10.1056/Nejmc1703047 |
0.324 |
|
| 2017 |
Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, ... ... Miller WH, et al. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European Journal of Cancer (Oxford, England : 1990). 79: 176-184. PMID 28501764 DOI: 10.1016/J.Ejca.2017.04.007 |
0.324 |
|
| 2017 |
Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, et al. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Breast Cancer Research : Bcr. 19: 54. PMID 28464908 DOI: 10.1186/S13058-017-0836-3 |
0.307 |
|
| 2017 |
Chang CH, Bijian K, Qiu D, Su J, Saad A, Dahabieh MS, Miller WH, Alaoui-Jamali MA. Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells. Oncotarget. PMID 28415719 DOI: 10.18632/Oncotarget.16105 |
0.324 |
|
| 2017 |
D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH, Mohr P, Marquez-Rodas I, Charles J, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 226-235. PMID 28056206 DOI: 10.1200/Jco.2016.67.9258 |
0.343 |
|
| 2017 |
Soria J, Rodon Ahnert J, Berger R, Miller WH, Brana I, Loriot Y, Mughal TI, Lazar V, Wunder F, Bresson C, Koscielny S, Afshar M, Saintigny P, Tsimberidou AM, Richon C, et al. WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies. Journal of Clinical Oncology. 35: TPS11625-TPS11625. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps11625 |
0.352 |
|
| 2017 |
Ascierto PA, Bechter O, Wolter P, Lebbe C, Elez E, Miller WH, Long GV, Omlin AG, Siena S, Calvo E, Pickard M, Gollerkeri A, Wollenberg L, Germa C, Dummer R. A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma. Journal of Clinical Oncology. 35: 9518-9518. DOI: 10.1200/Jco.2017.35.15_Suppl.9518 |
0.354 |
|
| 2017 |
Gasal E, Fernandez AMA, Ascierto PA, Atkinson V, Dummer R, Flaherty KT, Grob J, Hansson J, Hassel J, Larkin J, Lebbé C, Long GV, Lorigan P, Miller W, Nathan P, et al. 1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx377.044 |
0.32 |
|
| 2016 |
Ferrario C, Strepponi I, Esfahani K, Charamis H, Langleben A, Scarpi E, Nanni O, Miller WH, Panasci LC. Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. Plos One. 11: e0167906. PMID 27992451 DOI: 10.1371/Journal.Pone.0167906 |
0.335 |
|
| 2016 |
Nichol JN, Galbraith MD, Kleinman CL, Espinosa JM, Miller WH. NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia. Cell Reports. 14: 2938-49. PMID 26997274 DOI: 10.1016/J.Celrep.2016.02.074 |
0.342 |
|
| 2016 |
Long GV, Hamid O, Hodi FS, Lawrence DP, Atkinson V, Starodub A, Carlino MS, Fisher RA, Miller WH, Maio M, Butler M, Queirolo P, Ferrucci PF, Petrella TM, Schachter J, et al. Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022). Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps9596 |
0.34 |
|
| 2016 |
Bendell JC, Kim TW, Goh BC, Wallin J, Oh D, Han S, Lee CB, Hellmann MD, Desai J, Lewin JH, Solomon BJ, Chow LQM, Miller WH, Gainor JF, Flaherty K, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). Journal of Clinical Oncology. 34: 3502-3502. DOI: 10.1200/Jco.2016.34.15_Suppl.3502 |
0.365 |
|
| 2016 |
Ribas A, Hodi FS, Lawrence DP, Atkinson V, Starodub A, Carlino MS, Fisher RA, Long GV, Miller WH, Huang Y, Diede SJ, Ebbinghaus S, Hamid O. Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study. Journal of Clinical Oncology. 34: 3014-3014. DOI: 10.1200/Jco.2016.34.15_Suppl.3014 |
0.315 |
|
| 2016 |
Guo Q, Rincon SVd, Goncalves C, Miller WH. Abstract 686: MNK1 promotes the progression of breast ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) Cancer Research. 76: 686-686. DOI: 10.1158/1538-7445.Am2016-686 |
0.318 |
|
| 2016 |
Razak A, Gore L, Britten CD, Miller WH, Uy GL, Nichols G, Middleton S, Blotner S, Zhi J, Jukofsky L, Pierceall W, Higgins B, Chen LC. A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors European Journal of Cancer. 69. DOI: 10.1016/S0959-8049(16)32645-4 |
0.323 |
|
| 2015 |
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, ... ... Miller WH, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26014293 DOI: 10.1200/Jco.2014.58.3377 |
0.312 |
|
| 2015 |
Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 25908602 DOI: 10.1093/Annonc/Mdv191 |
0.325 |
|
| 2015 |
Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH, Karsh LI, Tcherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. Journal For Immunotherapy of Cancer. 3: 14. PMID 25901286 DOI: 10.1186/S40425-015-0055-3 |
0.318 |
|
| 2015 |
Hoffer LJ, Robitaille L, Zakarian R, Melnychuk D, Kavan P, Agulnik J, Cohen V, Small D, Miller WH. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. Plos One. 10: e0120228. PMID 25848948 DOI: 10.1371/Journal.Pone.0120228 |
0.349 |
|
| 2015 |
Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet. Oncology. 16: 375-84. PMID 25795410 DOI: 10.1016/S1470-2045(15)70076-8 |
0.368 |
|
| 2015 |
Zhan Y, Dahabieh MS, Rajakumar A, Dobocan MC, M'Boutchou MN, Goncalves C, Shiru L L, Pettersson F, Topisirovic I, van Kempen L, Del Rincón SV, Miller WH. The role of eIF4E in response and acquired resistance to vemurafenib in melanoma. The Journal of Investigative Dermatology. 135: 1368-76. PMID 25615552 DOI: 10.1038/Jid.2015.11 |
0.348 |
|
| 2015 |
Pettersson F, Del Rincon SV, Emond A, Huor B, Ngan E, Ng J, Dobocan MC, Siegel PM, Miller WH. Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis. Cancer Research. 75: 1102-12. PMID 25608710 DOI: 10.1158/0008-5472.Can-14-1996 |
0.317 |
|
| 2015 |
Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH, Borden KL. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. Haematologica. 100: e7-9. PMID 25425688 DOI: 10.3324/Haematol.2014.111245 |
0.364 |
|
| 2015 |
Robichaud N, del Rincon SV, Huor B, Alain T, Petruccelli LA, Hearnden J, Goncalves C, Grotegut S, Spruck CH, Furic L, Larsson O, Muller WJ, Miller WH, Sonenberg N. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene. 34: 2032-42. PMID 24909168 DOI: 10.1038/Onc.2014.146 |
0.322 |
|
| 2015 |
Jamal R, Kempen LV, Thebault P, Belanger K, Friedmann JE, Ayoub JM, Cocolakis E, Kazemi S, Dionne J, Lambert C, Le H, Grange C, Cailhier J, Spatz A, Lapointe R, ... Miller WH, et al. One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). Journal of Clinical Oncology. 33: 9062-9062. DOI: 10.1200/Jco.2015.33.15_Suppl.9062 |
0.348 |
|
| 2015 |
Sullivan RJ, Weber JS, Patel SP, Dummer R, Miller WH, Cosgrove D, Carlino MS, Tan DS, Lebbe C, Cipani T, Elez E, Maacke H, Nikolopoulos P, Aout M, Parseval LAD, et al. A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. Journal of Clinical Oncology. 33: 9007-9007. DOI: 10.1200/Jco.2015.33.15_Suppl.9007 |
0.352 |
|
| 2015 |
Ribas A, Butler M, Lutzky J, Lawrence DP, Robert C, Miller W, Linette GP, Ascierto PA, Kuzel T, Algazi AP, Postow MA, Nathan PD, Curti BD, Robbins PB, Li X, et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. Journal of Clinical Oncology. 33: 3003-3003. DOI: 10.1200/Jco.2015.33.15_Suppl.3003 |
0.322 |
|
| 2015 |
Lapointe R, Jamal R, Kempen Lv, Thebault P, Belanger K, Friedmann J, Ayoub J, Cocolakis E, Kazemi S, Dionne J, Lambert C, Le H, Grange C, Cailhier J, Spatz A, ... Miller W, et al. Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM) Journal For Immunotherapy of Cancer. 3: 259. DOI: 10.1186/2051-1426-3-S2-P259 |
0.325 |
|
| 2015 |
Dummer R, Sandhu S, Hassel JC, Muñoz E, Berking C, Gesierich A, Ascierto PA, Esposito O, Carter K, Antona V, Radhakrishnan R, Cui X, Caponigro G, Jaeger S, Demuth T, ... Miller WH, et al. 3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31828-7 |
0.327 |
|
| 2014 |
Hauschild A, Grobb J, Demidov L, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank C, Miller W, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion Sileni V, Aktan G, Haney P, et al. 1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv378. PMID 28171162 DOI: 10.1093/Annonc/Mdu344.8 |
0.323 |
|
| 2014 |
Taylor M, Sosman J, Gonzalez R, Carlino MS, Kittaneh M, Lolkema MP, Miller W, Marino A, Zhang V, Bhansali SG, Parasuraman S, Postow MA. 1086OPHASE IB/II STUDY OF LEE011 (CDK4/6 INHIBITOR) AND LGX818 (BRAF INHIBITOR) IN BRAF-MUTANT MELANOMA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv374-iv375. PMID 28171139 DOI: 10.1093/Annonc/Mdu344.2 |
0.332 |
|
| 2014 |
Nielsen TH, Diaz Z, Christodoulopoulos R, Charbonneau F, Qureshi S, Rousseau C, Benlimame N, Camlioglu E, Constantin AM, Oros KK, Krumsiek J, Crump M, Morin RD, Cerchietti L, Johnson NA, ... ... Miller WH, et al. Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 2688-93. PMID 25472678 DOI: 10.1158/1055-9965.Epi-14-0549 |
0.327 |
|
| 2014 |
Pettersson F, Del Rincon SV, Miller WH. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond. Expert Opinion On Therapeutic Targets. 18: 1035-48. PMID 25004955 DOI: 10.1517/14728222.2014.937426 |
0.305 |
|
| 2014 |
Nichol JN, Garnier N, Miller WH. Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide. Best Practice & Research. Clinical Haematology. 27: 19-31. PMID 24907014 DOI: 10.1016/J.Beha.2014.04.009 |
0.321 |
|
| 2014 |
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, ... ... Miller WH, et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 511: 90-3. PMID 24870236 DOI: 10.1038/Nature13283 |
0.338 |
|
| 2014 |
Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, et al. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. Journal For Immunotherapy of Cancer. 2: 2. PMID 24829759 DOI: 10.1186/2051-1426-2-2 |
0.305 |
|
| 2014 |
Grob JJ, Amonkar MM, Martin-Algarra S, Demidov LV, Goodman V, Grotzinger K, Haney P, Kämpgen E, Karaszewska B, Mauch C, Miller WH, Millward M, Mirakhur B, Rutkowski P, Chiarion-Sileni V, et al. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 1428-36. PMID 24769640 DOI: 10.1093/Annonc/Mdu154 |
0.302 |
|
| 2014 |
Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH, Mandalà M, Hospers GA, Arance A, Queirolo P, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. The Lancet. Oncology. 15: 436-44. PMID 24582505 DOI: 10.1016/S1470-2045(14)70051-8 |
0.325 |
|
| 2014 |
Garnier N, Redstone GG, Dahabieh MS, Nichol JN, del Rincon SV, Gu Y, Bohle DS, Sun Y, Conklin DS, Mann KK, Miller WH. The novel arsenical darinaparsin is transported by cystine importing systems. Molecular Pharmacology. 85: 576-85. PMID 24431147 DOI: 10.1124/Mol.113.089433 |
0.334 |
|
| 2014 |
Jamal R, Belanger K, Friedmann JE, Ayoub JM, Cocolakis E, Kazemi S, Dionne J, Lambert C, Le H, Kempen LV, Spatz A, Lapointe R, Miller WH. A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). Journal of Clinical Oncology. 32: 9066-9066. DOI: 10.1200/Jco.2014.32.15_Suppl.9066 |
0.371 |
|
| 2014 |
Siu LL, Italiano A, Miller WH, Blay J, Gietema JA, Bang Y, Mileshkin LR, Hirte HW, Reckner M, Higgins B, Jukofsky L, Blotner S, Zhi J, Middleton S, Nichols GL, et al. Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. Journal of Clinical Oncology. 32: 2535-2535. DOI: 10.1200/Jco.2014.32.15_Suppl.2535 |
0.316 |
|
| 2014 |
Kefford R, Sullivan RJ, Miller WH, Elez EM, Tan D, Kim KB, Long GV, Flaherty KT, Tai D, Stutvoet S, Maacke H, Whiley M, Parseval LM, Tabernero J. Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results Journal of Translational Medicine. 12: 5. DOI: 10.1186/1479-5876-12-S1-P5 |
0.338 |
|
| 2014 |
Dupéré-Richer D, Kinal M, Pettersson F, Hassawi M, ShaoNing Y, Nielsen TH, Klein K, Ezponda-Itoiz T, Licht JD, Johnson N, Assouline SE, Cerchietti L, Miller WH, Mann KK. Abstract 5538: Development of HDACi resistance in DLBCL leads to a switch in subtype towards a more differentiated B-cell and is associated with increased sensitivity to proteasome inhibition Cancer Research. 74: 5538-5538. DOI: 10.1158/1538-7445.Am2014-5538 |
0.38 |
|
| 2014 |
Redstone GGJ, Nichol JN, Faubert B, Jones RG, Mann KK, Miller WH. Abstract 491: Selective killing of oncogenically transformed cells by arsenic trioxide and trolox Cancer Research. 74: 491-491. DOI: 10.1158/1538-7445.Am2014-491 |
0.352 |
|
| 2014 |
Zhan Y, Dahabieh MS, Pettersson F, Dobocan MC, Boutchou MNM, Kempen LV, Rincon SVd, Miller WH. Abstract 3710: The role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to Vemurafenib in melanoma Cancer Research. 74: 3710-3710. DOI: 10.1158/1538-7445.Am2014-3710 |
0.361 |
|
| 2014 |
Weber JS, Minor DR, D'Angelo SP, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Grob J, Lao C, Linette G, Grossmann K, Hassel JC, Lorigan P, et al. Lba3_Pra Phase 3 Randomized, Open-Label Study Of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) In Patients With Advanced Melanoma After Prior Anti-Ctla-4 Therapy Annals of Oncology. 25. DOI: 10.1093/Annonc/Mdu438.34 |
0.341 |
|
| 2013 |
Guilbert C, Annis MG, Dong Z, Siegel PM, Miller WH, Mann KK. Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer. Plos One. 8: e85995. PMID 24392034 DOI: 10.1371/Journal.Pone.0085995 |
0.381 |
|
| 2013 |
Martinez-Marignac V, Shawi M, Pinedo-Carpio E, Wang X, Panasci L, Miller W, Pettersson F, Aloyz R. Pharmacological targeting of eIF4E in primary CLL lymphocytes. Blood Cancer Journal. 3: e146. PMID 24036945 DOI: 10.1038/Bcj.2013.43 |
0.37 |
|
| 2013 |
Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, ... ... Miller WH, et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2870-8. PMID 23857972 DOI: 10.1200/Jco.2012.43.3391 |
0.374 |
|
| 2013 |
Palumbo MO, Kavan P, Miller WH, Panasci L, Assouline S, Johnson N, Cohen V, Patenaude F, Pollak M, Jagoe RT, Batist G. Systemic cancer therapy: achievements and challenges that lie ahead. Frontiers in Pharmacology. 4: 57. PMID 23675348 DOI: 10.3389/Fphar.2013.00057 |
0.303 |
|
| 2013 |
Jimeno A, Weiss GJ, Miller WH, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2766-74. PMID 23575478 DOI: 10.1158/1078-0432.Ccr-12-3654 |
0.335 |
|
| 2013 |
Petruccelli LA, Pettersson F, Del Rincón SV, Guilbert C, Licht JD, Miller WH. Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitor-induced DNA damage and apoptosis. Molecular Cancer Therapeutics. 12: 1591-604. PMID 23536727 DOI: 10.1158/1535-7163.Mct-12-1039 |
0.316 |
|
| 2013 |
Garnier N, Petruccelli LA, Molina MF, Kourelis M, Kwan S, Diaz Z, Schipper HM, Gupta A, del Rincon SV, Mann KK, Miller WH. The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells. Leukemia. 27: 2220-8. PMID 23426167 DOI: 10.1038/Leu.2013.54 |
0.374 |
|
| 2013 |
Nielsen TH, Johnson N, Garnier N, Kwan S, Yao L, Cocolakis E, Hébert J, Morgan RA, Paquet E, Callahan KP, Jordan CT, Assouline S, Miller WH, Mann KK. Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient. Frontiers in Pharmacology. 4: 9. PMID 23408639 DOI: 10.3389/Fphar.2013.00009 |
0.367 |
|
| 2013 |
Dupéré-Richer D, Kinal M, Ménasché V, Nielsen TH, Del Rincon S, Pettersson F, Miller WH. Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance. Cell Death & Disease. 4: e486. PMID 23392174 DOI: 10.1038/Cddis.2012.210 |
0.346 |
|
| 2013 |
Lassen U, Miller WH, Hotte S, Evans TR, Kollmansberger C, Adamson D, Nielsen DL, Spicer J, Chen E, Meyer T, Brown K, Rafi R, Sawyer MB. Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. Cancer Chemotherapy and Pharmacology. 71: 543-9. PMID 23196640 DOI: 10.1007/S00280-012-2038-0 |
0.32 |
|
| 2013 |
Larkin JMG, Vecchio MD, Ascierto PA, Schachter J, Garbe C, Neyns B, Mandala M, Lorigan P, Miller WH, Guminski AD, Berking C, Rutkowski P, Queirolo P, Hauschild A, Arance AM, et al. Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma. Journal of Clinical Oncology. 31: 9046-9046. DOI: 10.1200/Jco.2013.31.15_Suppl.9046 |
0.302 |
|
| 2013 |
Kefford R, Miller WH, Tan DS, Sullivan RJ, Long G, Dienstmann R, Tai WMD, Flaherty K, Stutvoet S, Schumacher KM, Wandel S, Parseval LAD, Tabernero J. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. Journal of Clinical Oncology. 31: 9029-9029. DOI: 10.1200/Jco.2013.31.15_Suppl.9029 |
0.39 |
|
| 2013 |
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Mirakhur B, et al. An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). Journal of Clinical Oncology. 31: 9013-9013. DOI: 10.1200/Jco.2013.31.15_Suppl.9013 |
0.316 |
|
| 2013 |
Chia SKL, Ellard S, Mates M, Welch S, Mihalcioiu CLD, Miller WH, Gelmon KA, Lohrisch CA, Kumar V, Taylor SK, Hagerman L, Eisenhauer EA, Bradbury PA. A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198. Journal of Clinical Oncology. 31: 518-518. DOI: 10.1200/Jco.2013.31.15_Suppl.518 |
0.375 |
|
| 2013 |
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Amri A, Gendron P, Romeo AA, Morris S, Jaquith J, Cormack G, Cocolakis E, Bergeron J, Cerchietti L, Leber B, Miller WH, Borden KL. A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1 Blood. 122: 821-821. DOI: 10.1182/Blood.V122.21.821.821 |
0.367 |
|
| 2013 |
Dupéré-Richer D, Kinal M, Pettersson F, Miller WH. Resistance To Vorinostat In Hematological Malignancies May Involve Cytoprotective UPR and Correlates With Increased Sensitivity To Bortezomib-Induced Cell Death Blood. 122: 5137-5137. DOI: 10.1182/Blood.V122.21.5137.5137 |
0.356 |
|
| 2013 |
Guilbert C, Annis MG, Siegel P, Miller WH, Mann KK. Abstract 942: Decreasing the AKT feedback loop with arsenic trioxide enhances mTORi anti-tumor effects. Cancer Research. 73: 942-942. DOI: 10.1158/1538-7445.Am2013-942 |
0.401 |
|
| 2013 |
Pettersson F, Emond A, Huor B, Rincon Sd, Miller WH. Abstract 857: Anti-tumor and anti-metastatic activity of the eIF4E-targeted drug ribavirin in human and murine models of breast cancer. Cancer Research. 73: 857-857. DOI: 10.1158/1538-7445.Am2013-857 |
0.394 |
|
| 2013 |
Nielsen TH, Diaz Z, Christodoulopoulos R, Yao L, Qureshi S, Benlimame N, Camlioglu E, Crump M, Morin RD, Johnson N, Haliotis TP, Miller WH, Assouline S, Mann KK. Abstract 64: Quality and feasibility of a protocol for simultaneous isolation of RNA, DNA and tissue for IHC from needle core lymph node biopsies in DLBCL adapted for multi-center trials. Cancer Research. 73: 64-64. DOI: 10.1158/1538-7445.Am2013-64 |
0.327 |
|
| 2013 |
Zhan Y, Dahabieh MS, Rincon SVd, Miller WH. Abstract B235: The role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to vemurafenib in melanoma. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B235 |
0.38 |
|
| 2013 |
Emond A, Rincon SVD, Huor B, Pettersson F, Miller WH. Abstract A154: Inhibition of eIF4E with Ribavirin suppresses EMT and breast cancer invasiveness. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A154 |
0.385 |
|
| 2012 |
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, MartÃn-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 380: 358-65. PMID 22735384 DOI: 10.1016/S0140-6736(12)60868-X |
0.312 |
|
| 2012 |
Ferrario C, Miller WH, Charamis H, Langleben A, Batist G, Scarpi E, Nanni O, Panasci LC. Phase II trial of sorafenib (S) and vinorelbine (V) in metastatic breast cancer (mBC) with pharmacokinetics (PK) analysis. Journal of Clinical Oncology. 30: 1099-1099. DOI: 10.1200/Jco.2012.30.15_Suppl.1099 |
0.311 |
|
| 2012 |
Kwan S, Garnier N, Miller WH, Mann KK. Abstract 4890: Arsenic trioxide induces apoptosis through the activation of ASK1 and is enhanced by a thioredoxin reductase inhibitor Cancer Research. 72: 4890-4890. DOI: 10.1158/1538-7445.Am2012-4890 |
0.374 |
|
| 2012 |
Dupéré-Richer D, Kinal M, Pettersson F, Rincon SD, Miller WH. Abstract 4707: Inhibition of autophagy overcomes acquired resistance to vorinostat Cancer Research. 72: 4707-4707. DOI: 10.1158/1538-7445.Am2012-4707 |
0.388 |
|
| 2012 |
Ferrario C, Miller WH, Charamis H, Langleben A, Oyewole-Eletu S, Dalfen R, Patenaude F, Batist G, Panasci LC. Abstract 2706: Phase 2 study with pharmacokinetics (PK) analysis of sorafenib and vinorelbine in metastatic breast cancer Cancer Research. 72: 2706-2706. DOI: 10.1158/1538-7445.Am2012-2706 |
0.377 |
|
| 2011 |
Sahebjam S, Aloyz R, Pilavdzic D, Brisson M, Ferrario C, Bouganim N, Cohen V, Miller WH, Panasci LC. The role of Ki-67 proliferation index vis-à-vis Oncotype DX. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e11055. PMID 28023425 DOI: 10.1200/Jco.2011.29.15_Suppl.E11055 |
0.31 |
|
| 2011 |
Rudin CM, Jimeno A, Miller WH, Eigl BJ, Gettinger SN, Chang AL, Faia K, Sweeney J, Loewen G, Ross RW, Weiss GJ. A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3014. PMID 28022161 DOI: 10.1200/Jco.2011.29.15_Suppl.3014 |
0.376 |
|
| 2011 |
Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller WH, Bagalà C, Ferraro DA, Colombi F, Cagnazzo C, Gioeni L, Fly KD, Huang B, Leone F. Final toxicity results of a phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naive patients (pts) with metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4081. PMID 28020455 DOI: 10.1200/Jco.2011.29.15_Suppl.4081 |
0.361 |
|
| 2011 |
Batist G, Wu JH, Spatz A, Miller WH, Cocolakis E, Rousseau C, Diaz Z, Ferrario C, Basik M. Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies. Frontiers in Pharmacology. 2: 59. PMID 22007174 DOI: 10.3389/Fphar.2011.00059 |
0.351 |
|
| 2011 |
Soye KJ, Trottier C, Richardson CD, Ward BJ, Miller WH. RIG-I is required for the inhibition of measles virus by retinoids. Plos One. 6: e22323. PMID 21811588 DOI: 10.1371/Journal.Pone.0022323 |
0.301 |
|
| 2011 |
Petruccelli LA, Dupéré-Richer D, Pettersson F, Retrouvey H, Skoulikas S, Miller WH. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. Plos One. 6: e20987. PMID 21695163 DOI: 10.1371/Journal.Pone.0020987 |
0.312 |
|
| 2011 |
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine. 364: 2517-26. PMID 21639810 DOI: 10.1056/Nejmoa1104621 |
0.33 |
|
| 2011 |
Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Retrouvay H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KL, Benz CC, Miller WH. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2874-84. PMID 21415224 DOI: 10.1158/1078-0432.Ccr-10-2334 |
0.346 |
|
| 2011 |
Pettersson F, Miller WH, Nervi C, Gronemeyer HJ, Licht J, Tallman MS, Waxman S. The 12th international conference on differentiation therapy: targeting the aberrant growth, differentiation and cell death programs of cancer cells. Cell Death and Differentiation. 18: 1231-3. PMID 21212795 DOI: 10.1038/Cdd.2010.173 |
0.312 |
|
| 2011 |
Mann KK, Johnson N, Nielsen TH, Garnier N, Kwan S, Cocolakis E, Hebert J, Morgan R, Miller WH. Targeting EVI1-Overexpressing AML with Darinaparsin Blood. 118: 4269-4269. DOI: 10.1182/Blood.V118.21.4269.4269 |
0.403 |
|
| 2011 |
Assouline S, Kraljacic-Culjkovic B, Cocolakis E, Amri A, Bergeron J, Jamal R, Miller WH, Borden KL. A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E, Blood. 118: 3606-3606. DOI: 10.1182/Blood.V118.21.3606.3606 |
0.416 |
|
| 2011 |
Garnier NM, Kourelis M, Flores M, Mann KK, Miller WH. Abstract 5360: Differential induction of the anti-oxidant response by arsenic trioxide and darinaparsin in leukemic cells Cancer Research. 71: 5360-5360. DOI: 10.1158/1538-7445.Am2011-5360 |
0.357 |
|
| 2011 |
Petruccelli LA, Rice KL, Pettersson F, Nichol JN, Skoulikas S, Licht JD, Miller WH. Abstract 2136: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors Cancer Research. 71: 2136-2136. DOI: 10.1158/1538-7445.Am2011-2136 |
0.356 |
|
| 2011 |
Nielsen TH, Nichol J, Assouline S, Mann KK, Miller WH. Abstract B83: Combination therapy with the histone deacetylase inhibitor panobinostat and the CD20-targeting antibody rituximab in diffuse large B-cell lymphoma. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B83 |
0.363 |
|
| 2010 |
Cohen V, Agulnik JS, Ang C, Kasymjanova G, Batist G, Small D, Brandao G, Chong G, Miller WH. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer. 116: 4309-17. PMID 20549828 DOI: 10.1002/Cncr.25214 |
0.304 |
|
| 2010 |
McNamara S, Nichol JN, Wang H, Miller WH. Targeting PKC delta-mediated topoisomerase II beta overexpression subverts the differentiation block in a retinoic acid-resistant APL cell line. Leukemia. 24: 729-39. PMID 20200558 DOI: 10.1038/Leu.2010.27 |
0.324 |
|
| 2010 |
Hamel S, Bouchard A, Ferrario C, Hassan S, Aguilar-Mahecha A, Buchanan M, Quenneville L, Miller W, Basik M. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers Breast Cancer Research and Treatment. 120: 47-57. PMID 19301121 DOI: 10.1007/S10549-009-0364-7 |
0.334 |
|
| 2010 |
Ferrario C, Charamis H, Oyewole-Eletu S, Mihalcioiu CL, Langleben A, Miller WH, Aloyz R, Panasci LC. Phase Ib study of sorafenib and vinorelbine as first-line treatment in patients with metastatic breast cancer. Journal of Clinical Oncology. 28: 1093-1093. DOI: 10.1200/Jco.2010.28.15_Suppl.1093 |
0.378 |
|
| 2010 |
Langleben A, Supko JG, Hotte S, Lorusso P, Miller WH, Hurtubise A, Leggett DS, Li W, Borodyanski L, Li CJ. Abstract LB-171: A phase 1 dose escalation study of BBI608, a first-in-class cancer stem cell pathway inhibitor in patients with advanced malignancies Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-171 |
0.334 |
|
| 2010 |
Nielsen TH, Petruccelli LA, Dobocan MC, Petterson F, Haliotis TP, Assouline S, Mann KK, Miller WH. Abstract 5449: Histone deacetylase inhibitor treatment in B-cell non-Hodgkin's lymphoma - effect ofex vivotreatment on primary patient samples Cancer Research. 70: 5449-5449. DOI: 10.1158/1538-7445.Am10-5449 |
0.355 |
|
| 2010 |
Pettersson F, Dobocan MC, Retrouvay H, Culjkovic B, Amri A, Gaboury L, Borden KLB, Miller WH. Abstract 3165: Anti-tumor activity of the eIF4E-targeted drug ribavirin in breast cancer cells Cancer Research. 70: 3165-3165. DOI: 10.1158/1538-7445.Am10-3165 |
0.409 |
|
| 2009 |
Speranza G, Cohen V, Agulnik JS, Chong G, Meilleur F, Brandao G, Kasymjanova G, Small D, Miller WH. Molecular changes in epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) biopsies at time of progression compared to initial biopsy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e22066. PMID 27963209 DOI: 10.1200/Jco.2009.27.15_Suppl.E22066 |
0.304 |
|
| 2009 |
Bhatia S, Heath E, Puzanov I, Miller W, Curti B, Gordon M, Ernstoff M, Hausman D, Hunder N, Thompson J. Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3023. PMID 27962069 DOI: 10.1200/Jco.2009.27.15_Suppl.3023 |
0.356 |
|
| 2009 |
Lossos I, Craig MD, Tallman MS, Boccia RV, Conkling PR, Becerra C, Komarnitsky PB, Hamilton BL, Lewis J, Miller WH. Novel organic arsenic molecule darinaparsin: Development of IV and oral forms. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8501. PMID 27960853 DOI: 10.1200/Jco.2009.27.15_Suppl.8501 |
0.325 |
|
| 2009 |
Mann KK, Wallner B, Lossos IS, Miller WH. Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opinion On Investigational Drugs. 18: 1727-34. PMID 19780704 DOI: 10.1517/13543780903282759 |
0.316 |
|
| 2009 |
Power P, Stuart G, Oza A, Provencher D, Bentley JR, Miller WH, Pouliot JF. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecologic Oncology. 114: 410-4. PMID 19520420 DOI: 10.1016/J.Ygyno.2009.04.037 |
0.367 |
|
| 2009 |
Eisen T, Thomas J, Miller WH, Gore M, Wolter P, Kavan P, MartÃn JA, Lardelli P. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Melanoma Research. 19: 185-92. PMID 19436178 DOI: 10.1097/Cmr.0B013E32832Bbde6 |
0.38 |
|
| 2009 |
Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH, Borden KL. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 114: 257-60. PMID 19433856 DOI: 10.1182/Blood-2009-02-205153 |
0.322 |
|
| 2009 |
Batist G, Gelmon KA, Chi KN, Miller WH, Chia SK, Mayer LD, Swenson CE, Janoff AS, Louie AC. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 692-700. PMID 19147776 DOI: 10.1158/1078-0432.Ccr-08-0515 |
0.316 |
|
| 2009 |
Laurenzana A, Petruccelli LA, Pettersson F, Figueroa ME, Melnick A, Baldwin AS, Paoletti F, Miller WH. Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. Cancer Research. 69: 55-64. PMID 19117987 DOI: 10.1158/0008-5472.Can-08-0245 |
0.335 |
|
| 2009 |
Eisen T, Thatcher N, Leyvraz S, Miller WH, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 64: 60-5. PMID 18692272 DOI: 10.1016/J.Lungcan.2008.06.017 |
0.4 |
|
| 2009 |
Sebag M, Huang X, Garnier N, Miller WH, Mann K. Trolox Improves the Sensitivity of Multiple Myeloma to Arsenic Trioxide in Vitro and In Vivo. Blood. 114: 4920-4920. DOI: 10.1182/Blood.V114.22.4920.4920 |
0.389 |
|
| 2009 |
Miller WH, Lossos IS, Conkling PR, Becerra C, Tallman MS, Buck J, Wallner B, Lewis J. Darinaparsin a Novel Organic Arsenic Molecule Active in Lymphoma: Development of An Oral Form. Blood. 114: 4759-4759. DOI: 10.1182/Blood.V114.22.4759.4759 |
0.368 |
|
| 2009 |
Assouline SE, Cocolakis E, Rousseau C, Culjkovic B, Beslu N, Amri A, Caplan SN, Leber B, Roy D, Borden KLB, Miller WH. Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia. Blood. 114: 2085-2085. DOI: 10.1182/Blood.V114.22.2085.2085 |
0.42 |
|
| 2009 |
Petruccelli LA, Pettersson F, Dupere‐Richer D, Rice KL, Licht JD, Miller WH. Abstract A189: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A189 |
0.341 |
|
| 2009 |
Dupéré‐Richer D, Petruccelli L, Retrouvey H, Dobocan M, Tomenson M, Pettersson F, Miller WH. Abstract A188: Proapoptotic versus prosurvival function of the MAP kinase p38 induced by HDAC inhibitor in hematological malignant cells Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A188 |
0.34 |
|
| 2009 |
Garnier NM, Gu Y, Kourelis M, Mann KK, Bohle DS, Miller WH. Abstract A146: The role of cystine transport in darinaparsin‐induced cell death Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A146 |
0.363 |
|
| 2008 |
Diaz Z, Mann KK, Marcoux S, Kourelis M, Colombo M, Komarnitsky PB, Miller WH. A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia. 22: 1853-63. PMID 18633430 DOI: 10.1038/Leu.2008.194 |
0.304 |
|
| 2008 |
Mann KK, Colombo M, Miller WH. Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Molecular Cancer Therapeutics. 7: 1680-7. PMID 18566239 DOI: 10.1158/1535-7163.Mct-07-2164 |
0.329 |
|
| 2008 |
Trottier C, Chabot S, Mann KK, Colombo M, Chatterjee A, Miller WH, Ward BJ. Retinoids inhibit measles virus in vitro via nuclear retinoid receptor signaling pathways. Antiviral Research. 80: 45-53. PMID 18547655 DOI: 10.1016/J.Antiviral.2008.04.003 |
0.331 |
|
| 2008 |
Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 1969-74. PMID 18544557 DOI: 10.1093/Annonc/Mdn377 |
0.394 |
|
| 2008 |
Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 112: 981-9. PMID 18495956 DOI: 10.1182/Blood-2007-10-115873 |
0.346 |
|
| 2008 |
Blumenschein GR, Khuri FR, von Pawel J, Gatzemeier U, Miller WH, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1879-85. PMID 18398153 DOI: 10.1200/Jco.2007.12.2689 |
0.373 |
|
| 2008 |
McNamara S, Wang H, Hanna N, Miller WH. Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance. Molecular and Cellular Biology. 28: 2066-77. PMID 18212063 DOI: 10.1128/Mcb.01576-07 |
0.328 |
|
| 2008 |
Hotte SJ, Hirte HW, Moretto P, Iacobucci A, Wong D, Korz W, Miller WH. 405 POSTER Final results of a Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers Ejc Supplements. 6: 127. DOI: 10.1016/S1359-6349(08)72339-5 |
0.348 |
|
| 2008 |
Mann KK, Diaz Z, Marcoux S, Kourelis M, Colombo M, Komarnitsky PB, Abbadessa G, Miller WH. 264 POSTER A novel arsenical, darinaparsin, induces apoptosis in arsenic trioxide-resistant and MRP1/ABCC1-overexpressing cell lines Ejc Supplements. 6: 86. DOI: 10.1016/S1359-6349(08)72198-0 |
0.307 |
|
| 2007 |
Knox JJ, Figlin RA, Stadler WM, McDermott DF, Gabrail N, Miller WH, Hainsworth J, Ryan CW, Cupit L, Bukowski RM. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy Journal of Clinical Oncology. 25: 5011-5011. DOI: 10.1200/Jco.2007.25.18_Suppl.5011 |
0.333 |
|
| 2007 |
Batist G, Miller W, Mayer L, Janoff A, Swenson C, Louie A, Chi K, Chia S, Gelmon K. Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase I trial: A new approach for enhancing the activity of combination chemotherapy Journal of Clinical Oncology. 25: 2549-2549. DOI: 10.1200/Jco.2007.25.18_Suppl.2549 |
0.334 |
|
| 2006 |
Cohen V, Agulnik JS, Jarry J, Batist G, Small D, Kreisman H, Tejada NA, Miller WH, Chong G. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer. 107: 2858-65. PMID 17096434 DOI: 10.1002/Cncr.22331 |
0.306 |
|
| 2006 |
Bernardini S, Nuccetelli M, Noguera NI, Bellincampi L, Lunghi P, Bonati A, Mann K, Miller WH, Federici G, Lo Coco F. Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4. Annals of Hematology. 85: 681-7. PMID 16733740 DOI: 10.1007/S00277-006-0139-8 |
0.367 |
|
| 2006 |
Batist G, Chi K, Miller W, Chia S, Hasanbasic F, Fisic A, Mayer L, Swenson C, Janoff A, Gelmon K. Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors Journal of Clinical Oncology. 24: 2014-2014. DOI: 10.1200/Jco.2006.24.18_Suppl.2014 |
0.348 |
|
| 2006 |
Laurenzana A, Pettersson F, Miller WH. Role of PML/RARα in the pathogenesis of APL Drug Discovery Today: Disease Mechanisms. 3: 499-505. DOI: 10.1016/J.Ddmec.2006.11.008 |
0.304 |
|
| 2005 |
Mann KK, Padovani AM, Guo Q, Colosimo AL, Lee HY, Kurie JM, Miller WH. Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation. The Journal of Clinical Investigation. 115: 2924-33. PMID 16184197 DOI: 10.1172/Jci23628 |
0.314 |
|
| 2005 |
Chen EX, Batist G, Siu LL, Bangash N, Maclean M, McIntosh L, Miller WH, Oza AM, Lathia C, Petrenciuc O, Seymour L. Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. Investigational New Drugs. 23: 455-65. PMID 16133797 DOI: 10.1007/S10637-005-2905-1 |
0.345 |
|
| 2005 |
Diaz Z, Assaraf MI, Miller WH, Schipper HM. Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders. Journal of Neurochemistry. 93: 392-402. PMID 15816862 DOI: 10.1111/J.1471-4159.2005.03038.X |
0.309 |
|
| 2005 |
Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller WH, Panasci L, Lorimer IA, Batist G, Matthews S, Douglas L, Seymour L. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Investigational New Drugs. 23: 165-70. PMID 15744593 DOI: 10.1007/S10637-005-5862-9 |
0.357 |
|
| 2005 |
Goss G, Hirte H, Miller WH, Lorimer IA, Stewart D, Batist G, Parolin DA, Hanna P, Stafford S, Friedmann J, Walsh W, Mathews S, Douglas L, Seymour LK. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs. 23: 147-55. PMID 15744591 DOI: 10.1007/S10637-005-5860-Y |
0.35 |
|
| 2005 |
Diaz Z, Colombo M, Mann KK, Su H, Smith KN, Bohle DS, Schipper HM, Miller WH. Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood. 105: 1237-45. PMID 15466933 DOI: 10.1182/Blood-2004-05-1772 |
0.317 |
|
| 2005 |
Blumenschein GR, Khuri F, Gatzemeier U, Miller WH, Pawel Jv, Rigas JR, Herbst RS, Dziewanowska Z, Negro-Vilar A, Mabry M. A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 23. DOI: 10.1200/Jco.2005.23.16_Suppl.Lba7001 |
0.375 |
|
| 2005 |
Gatzemeier U, Blumenschein G, Jotte R, Pawel Jv, Miller W, Khuri E, Rigas J, Mabry M, Dziewanowska Z, Negro-Vilar A. O-086 A phase III randomized trial of carboplati/paclitaxel, with or without bexarotene (Targretin®), in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)80219-3 |
0.34 |
|
| 2004 |
Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3776-83. PMID 15365074 DOI: 10.1200/Jco.2004.12.082 |
0.364 |
|
| 2004 |
Côté S, McNamara S, Brambilla D, Bianchini A, Rizzo G, del Rincón SV, Grignani F, Nervi C, Miller WH. Expression of SMRTbeta promotes ligand-induced activation of mutated and wild-type retinoid receptors. Blood. 104: 4226-35. PMID 15319284 DOI: 10.1182/Blood-2003-10-3583 |
0.307 |
|
| 2004 |
Pettersson F, Couture MC, Hanna N, Miller WH. Enhanced retinoid-induced apoptosis of MDA-MB-231 breast cancer cells by PKC inhibitors involves activation of ERK. Oncogene. 23: 7053-66. PMID 15273718 DOI: 10.1038/Sj.Onc.1207956 |
0.327 |
|
| 2004 |
Witcher M, Shiu HY, Guo Q, Miller WH. Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells. Blood. 104: 3335-42. PMID 15256426 DOI: 10.1182/Blood-2004-01-0023 |
0.334 |
|
| 2004 |
Mann KK, Miller WH. Death by arsenic: implications of PML sumoylation. Cancer Cell. 5: 307-9. PMID 15093537 DOI: 10.1016/S1535-6108(04)00089-3 |
0.312 |
|
| 2004 |
Davison K, Mann KK, Waxman S, Miller WH. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood. 103: 3496-502. PMID 14701702 DOI: 10.1182/Blood-2003-05-1412 |
0.367 |
|
| 2003 |
Rousseau C, Pettersson F, Couture MC, Paquin A, Galipeau J, Mader S, Miller WH. The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 86: 1-14. PMID 12943740 DOI: 10.1016/S0960-0760(03)00255-3 |
0.328 |
|
| 2003 |
Davison K, Côté S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia. 17: 931-40. PMID 12750708 DOI: 10.1038/Sj.Leu.2402876 |
0.33 |
|
| 2003 |
Lin R, Wang TT, Miller WH, White JH. Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells. Endocrinology. 144: 749-53. PMID 12586749 DOI: 10.1210/En.2002-0026 |
0.319 |
|
| 2003 |
Witcher M, Ross DT, Rousseau C, Deluca L, Miller WH. Synergy between all-trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells. Blood. 102: 237-45. PMID 12586626 DOI: 10.1182/Blood-2002-09-2725 |
0.347 |
|
| 2003 |
Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH, Batist G, Patenaude F, Bangash N, Panarello L, Alaoui-Jamali M, Sausville E. SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 232-40. PMID 12525514 DOI: 10.1200/Jco.2003.03.047 |
0.321 |
|
| 2002 |
Mozziconacci MJ, Rosenauer A, Restouin A, Fanelli M, Shao W, Fernandez F, Toiron Y, Viscardi J, Gambacorti-Passerini C, Miller WH, Lafage-Pochitaloff M. Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones. Genes, Chromosomes & Cancer. 35: 261-70. PMID 12353268 DOI: 10.1002/Gcc.10117 |
0.332 |
|
| 2002 |
Côté S, Rosenauer A, Bianchini A, Seiter K, Vandewiele J, Nervi C, Miller WH. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood. 100: 2586-96. PMID 12239173 DOI: 10.1182/Blood-2002-02-0614 |
0.37 |
|
| 2002 |
Davison K, Mann KK, Miller WH. Arsenic trioxide: mechanisms of action. Seminars in Hematology. 39: 3-7. PMID 12012315 DOI: 10.1053/Shem.2002.33610 |
0.384 |
|
| 2002 |
Miller WH. Molecular targets of arsenic trioxide in malignant cells. The Oncologist. 7: 14-9. PMID 11961205 DOI: 10.1634/Theoncologist.7-Suppl_1-14 |
0.38 |
|
| 2001 |
Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP, Miller WH. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood. 98: 2651-6. PMID 11675334 DOI: 10.1182/Blood.V98.9.2651 |
0.331 |
|
| 2001 |
Mann KK, Shao W, Miller WH. The biology of acute promyelocytic leukemia. Current Oncology Reports. 3: 209-16. PMID 11296130 DOI: 10.1007/S11912-001-0052-1 |
0.354 |
|
| 2001 |
Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, Waxman S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood. 97: 264-9. PMID 11133770 DOI: 10.1182/Blood.V97.1.264 |
0.386 |
|
| 2000 |
Miller WH, Reyno LM, Loewen GR, Huan S, Winquist E, Moore M, Cato A, Jaunakais D, Truglia JA, Matthews S, Dancey J, Eisenhauer E. A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 11: 1387-9. PMID 11142476 DOI: 10.1023/A:1026579400806 |
0.342 |
|
| 2000 |
Côté S, Zhou D, Bianchini A, Nervi C, Gallagher RE, Miller WH. Altered ligand binding and transcriptional regulation by mutations in the PML/RARα ligand-binding domain arising in retinoic acid–resistant patients with acute promyelocytic leukemia Blood. 96: 3200-3208. DOI: 10.1182/Blood.V96.9.3200.H8003200_3200_3208 |
0.341 |
|
| 2000 |
Shao W, Rosenauer A, Mann K, Chang CB, Rachez C, Freedman LP, Miller WH. Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid–sensitive and –resistant acute promyelocytic leukemia cells Blood. 96: 2233-2239. DOI: 10.1182/Blood.V96.6.2233 |
0.304 |
|
| 1999 |
Park DJ, Chumakov AM, Vuong PT, Chih DY, Gombart AF, Miller WH, Koeffler HP. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. The Journal of Clinical Investigation. 103: 1399-408. PMID 10330422 DOI: 10.1172/Jci2887 |
0.338 |
|
| 1998 |
Miller WH. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer. 83: 1471-82. PMID 9781940 DOI: 10.1002/(Sici)1097-0142(19981015)83:8<1471::Aid-Cncr1>3.0.Co;2-6 |
0.37 |
|
| 1998 |
Samoszuk MK, Tynan W, Sallash G, Nasr S, Monczak Y, Miller WH. An immunofluorescent assay for acute promyelocytic leukemia cells. American Journal of Clinical Pathology. 109: 205-10. PMID 9583893 DOI: 10.1093/Ajcp/109.2.205 |
0.331 |
|
| 1998 |
Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 391: 811-4. PMID 9486654 DOI: 10.1038/35895 |
0.339 |
|
| 1998 |
Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, ... Miller WH, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. Journal of the National Cancer Institute. 90: 124-33. PMID 9450572 DOI: 10.1093/Jnci/90.2.124 |
0.377 |
|
| 1998 |
Müller S, Miller WH, Dejean A. Trivalent Antimonials Induce Degradation of the PML-RAR Oncoprotein and Reorganization of the Promyelocytic Leukemia Nuclear Bodies in Acute Promyelocytic Leukemia NB4 Cells Blood. 92: 4308-4316. DOI: 10.1182/Blood.V92.11.4308 |
0.346 |
|
| 1997 |
Monczak Y, Trudel M, Lamph WW, Miller WH. Induction of Apoptosis Without Differentiation by Retinoic Acid in PLB-985 Cells Requires the Activation of Both RAR and RXR Blood. 90: 3345-3355. DOI: 10.1182/Blood.V90.9.3345 |
0.338 |
|
| 1997 |
Chen G, Shi X, Tang W, Xiong S, Zhu J, Cai X, Han Z, Ni J, Shi G, Jia P, Liu M, He K, Niu C, Ma J, Zhang P, ... ... Miller W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) : I. As2O3 exerts dose-dependent dual effects on APL cells Blood. 89: 3345-3353. DOI: 10.1182/Blood.V89.9.3345 |
0.336 |
|
| 1997 |
Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH. A Retinoid-Resistant Acute Promyelocytic Leukemia Subclone Expresses a Dominant Negative PML-RARα Mutation Blood. 89: 4282-4289. DOI: 10.1182/Blood.V89.12.4282 |
0.345 |
|
| 1996 |
Rosenauer A, Raelson JV, Nervi C, Eydoux P, DeBlasio A, Miller WH. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines Blood. 88: 2671-2682. DOI: 10.1182/Blood.V88.7.2671.Bloodjournal8872671 |
0.358 |
|
| 1995 |
Spector NL, Hardy L, Ryan C, Miller WH, Humes JL, Nadler LM, Luedke E. 28-kDa mammalian heat shock protein, a novel substrate of a growth regulatory protease involved in differentiation of human leukemia cells. Journal of Biological Chemistry. 270: 1003-1006. PMID 7836350 DOI: 10.1074/Jbc.270.3.1003 |
0.302 |
|
| 1995 |
Bentel JM, Lebwohl DE, Cullen KJ, Rubin MS, Rosen N, Mendelsohn J, Miller WH. Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells. Journal of Cellular Physiology. 165: 212-21. PMID 7559803 DOI: 10.1002/Jcp.1041650124 |
0.309 |
|
| 1995 |
Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH, Zelenetz AD, Willman CL, Chen Z, Chen SJ, Zelent AZ, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 85: 1083-1094. DOI: 10.1182/Blood.V85.4.1083.Bloodjournal8541083 |
0.333 |
|
| 1995 |
Miller WH, Jakubowski A, Tong WP, Miller VA, Rigas JR, Benedetti F, Gill GM, Truglia JA, Ulm E, Shirley M, Warrell RP. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood. 85: 3021-3027. DOI: 10.1182/Blood.V85.11.3021.Bloodjournal85113021 |
0.331 |
|
| 1994 |
Dyck JA, Maul GG, Miller WH, Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein Cell. 76: 333-343. PMID 8293467 DOI: 10.1016/0092-8674(94)90340-9 |
0.329 |
|
| 1994 |
Frankel SR, Eardley A, Heller G, Berman E, Miller WH, Dmitrovsky E, Warrell RP. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Annals of Internal Medicine. 120: 278-86. PMID 8291820 DOI: 10.7326/0003-4819-120-4-199402150-00004 |
0.312 |
|
| 1994 |
Miller WH, Maerz WJ, Kurie J, Moy D, Baselga J, Lucas DA, Grippo JF, Masui H, Dmitrovsky E. All-trans-retinoic acid and hexamethylene bisacetamide (HMBA) regulate TGF-alpha and Hst-1/kFGF expression in differentiation sensitive but not in resistant human teratocarcinomas. Differentiation; Research in Biological Diversity. 55: 145-52. PMID 8143931 DOI: 10.1046/J.1432-0436.1994.5520145.X |
0.306 |
|
| 1994 |
Vahdat L, Maslak P, Miller W, Eardley A, Heller G, Scheinberg D, Warrell R. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid Blood. 84: 3843-3849. DOI: 10.1182/Blood.V84.11.3843.Bloodjournal84113843 |
0.344 |
|
| 1993 |
Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. Journal of the National Cancer Institute. 85: 1327-1333. PMID 8340945 DOI: 10.1093/Jnci/85.16.1327 |
0.341 |
|
| 1993 |
Motzer RJ, Dmitrovsky E, Miller WH, Tong WP, Bajorin DF, Scher HI, Bosl GJ. Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial Cancer. 72: 3313-3317. PMID 8242558 DOI: 10.1002/1097-0142(19931201)72:11<3313::Aid-Cncr2820721129>3.0.Co;2-C |
0.41 |
|
| 1992 |
Miller WH, Dmitrovsky E. Growth factors in human germ cell cancer. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 123: 183-9. PMID 1660620 DOI: 10.1007/978-3-642-84485-0_19 |
0.33 |
|
| 1992 |
Dmitrovsky E, Rodriguez E, Samaniego F, Reuter VE, Miller WH, Geller NL, Bosl GJ, Chaganti RS. Analysis of chromosome 12 abnormalities in male germ cell cancers. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 123: 119-23. PMID 1660617 DOI: 10.1007/978-3-642-84485-0_13 |
0.304 |
|
| 1992 |
Miller WH, Kakizuka A, Frankel SR, Warrell RP, DeBlasio A, Levine K, Evans RM, Dmitrovsky E. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 89: 2694-8. PMID 1372989 DOI: 10.1073/Pnas.89.7.2694 |
0.31 |
|
| 1992 |
Muindi J, Frankel SR, Miller WH, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood. 79: 299-303. PMID 1309668 DOI: 10.1182/Blood.V79.2.299.Bloodjournal792299 |
0.339 |
|
| 1991 |
Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). The New England Journal of Medicine. 324: 1385-93. PMID 1850498 DOI: 10.1056/Nejm199105163242002 |
0.339 |
|
| 1991 |
Kakizuka A, Miller WH, Umesono K, Warrell RP, Frankel SR, Murty VV, Dmitrovsky E, Evans RM. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 66: 663-74. PMID 1652368 DOI: 10.1016/0092-8674(91)90112-C |
0.334 |
|
| 1991 |
Miller WH, Dmitrovsky E. Oncogenes and clinical oncology. Current Opinion in Oncology. 3: 65-9. PMID 1646034 DOI: 10.1097/00001622-199102000-00010 |
0.336 |
|
| Show low-probability matches. |